Chinese biotech company Hutchmed is evolving its business strategy, targeting a faster path to profitability amid turbulent economic conditions. 15 November 2022
VectorY Therapeutics, a Dutch biotech developing vectorized antibody approaches for neurodegenerative diseases, has named Sander van Deventer, co-founder and fo 8 November 2022
Struggling in the wake of the discontinuation of ziritaxestat, Belgian biotech Galapagos is to undertake a radical restructuring aimed at jump-starting the busi 4 November 2022
Times are tough for cell medicine specialist Rubius Therapeutics (Nasdaq: RUBY), with the firm announcing plans to slash its workforce by 84%, part of a drastic 3 November 2022
The Belgian company, which is developing first-in-class treatments for demyelination-associated diseases, has announced Irene Knuesel as its new Chief Scientifi 21 October 2022
Abalos Therapeutics has announced the appointment of Thomas Bogenrieder as Chief Medical Officer (CMO). He brings over 17 years of international clinical develo 18 October 2022
After just a year in the role of chief medical officer and head of global clinical development at Californian biotech BioMarin, Harold Bernstein has taken a new 14 October 2022
T-CURX, a CAR-T cell spin-off from the University of Würzburg, has announced the appointment of its co-founder, Ulf Grawunder, as the chief executive of the com 6 October 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.